Female C57BL/6J mice (6–10-week-old) were purchased from the Animal Resources Centre (Canning Vale, WA, Australia). Mice were infected with 105 or 106 CCID50 of GETVMM2021 (Genbank ID; MN849355), 104 CCID50 CHIKV Reunion Island isolate, LR2006OPY1 (Genbank ID; DQ443544) or 104 CCID50 RRVTT (Genbank ID; KY302801) subcutaneously (s.c.) into the top/side of each hind foot as described previously [8 (link),54 (link)]. All virus preparations were mycoplasma free [84 (link)] as determined by MycoAlert Mycoplasma Detection Kit (Lonza, Basel, Switzerland). Serum viremia was determined by CCID50 assay, and foot swelling was determined using caliper height and width measurements, as described previously [8 (link),54 (link),85 (link)].
The JE/GETV formalin-inactivated vaccine (Nisseiken Co. Ltd., Tokyo, Japan) was used as described previously [8 (link)]. Mice were anesthetized with isoflurane and the vaccine was administered intramuscularly (i.m.) with the indicated dose split equally into both quadriceps muscles in 50 µL per muscle using an insulin syringe (Becton, Dickinson and Company, Franklin Lakes, NJ, USA).
The JE/GETV formalin-inactivated vaccine (Nisseiken Co. Ltd., Tokyo, Japan) was used as described previously [8 (link)]. Mice were anesthetized with isoflurane and the vaccine was administered intramuscularly (i.m.) with the indicated dose split equally into both quadriceps muscles in 50 µL per muscle using an insulin syringe (Becton, Dickinson and Company, Franklin Lakes, NJ, USA).
Free full text: Click here
